We present a critical analysis of the mechanism of reversible hydrogen evolution reaction based on thermodynamics of hydrogen processes considering atomic and ionic species as intermediates. Clear distinction between molecular hydrogen evolution/oxidation (H$_2$ER and H$_2$OR) and atomic hydrogen evolution/oxidation (HER and HOR) reactions is made. It is suggested that the main reaction describing reversible H$_2$ER and H$_2$OR in acidic and basic solutions is: $\ce{H3O^+} + 2e^- \xrightleftharpoons{\mathrm{({H}_{2}^{+}})_{ad}} \ce{H2} + \ce{OH^-}$, which proceeds via the formation of hydrogen molecular ion as intermediate and its potential is $E^{0}$ = 0.414~V (at the standard Hydrogen electrode SHE scale). We analyse experimentally reported data with models which provide \emph{quantitative} match (R.J.Kriek et al., Electrochem. Sci. Adv. e2100041 (2021)). The experimentally observed slope of $\lg(Current)$ vs. $Potential$ equal to $\approx 30$~mV/dec corroborates the presented model of H$_2$ER/H$_2$ER based on \ce{H2$^+$} as intermediate.

In hepatocellular carcinoma (HCC), recurrence usually occurs after curative surgical resection. Currently, no approved adjuvant therapy has been shown to reduce recurrence rates. In this report, the in vivo mouse effect of sequential combination treatment with recombinant mouse interferon-alpha (rmIFN-α) and an anti-mouse-PD1 antibody on hepatitis B virus (HBV) clearance was evaluated. A phase I clinical trial was then conducted to assess the safety, tolerability, and inhibitory activity of sequential therapy with ropeginterferon alfa-2b and nivolumab in HCC recurrence in patients who have undergone curative surgery for HBV-related HCC. In animal modeling, HBV suppression was significantly greater with rmIFN-α and anti-PD1 sequential combination treatment than with their treatment alone. In the Phase I study, eleven patients completed the sequential therapy with ropeginterferon alfa-2b every two weeks at the dose of 450 µg for six doses, followed by three doses of nivolumab every two weeks up to 0.75 mg/kg. A notable decrease or clearance of HBV surface antigen was observed in two patients. Dose-limiting toxicity of grade 3 alanine transaminase and aspartate aminotransferase increases was observed in one patient. The maximum tolerated dose was determined. Currently no HCC recurrence has been observed. The treatment modality was well tolerated. The data support further clinical development of sequential combination therapy as a post-surgery prophylactic measure against the recurrence of HBV-related HCC.

Volcanic emissions (ash, gas, aerosols) dispersed in the atmosphere during explosive eruptions generate hazards affecting aviation, human health, air quality and the environment. We document for the first time the contamination of airspace by very fine volcanic ash due to sequences of tran-sient ash plumes from Mount Etna. The atmospheric dispersal of sub-10 μm (PM10) ash is mod-elled using the WRF-Chem model coupled online with meteorology and aerosols and offline with Mass Eruption Rates (MER) derived from near-vent Doppler radar measurements and inferred plume altitudes. We analyse two sequences of paroxysms with widely varied volcanological conditions and contrasted meteorological synoptic patterns in October–December 2013 and on 3-5 December 2015. We analyse the PM10 ash dispersal simulation maps in terms of time-averaged columnar ash density, concentration at specified flight levels averaged over the entire sequence interval, and daily average concentration during selected paroxysm days at these flight levels. The very fine ash from such eruption sequences is shown to easily contaminate the airspace around the volcano within a radius of about 1000 km in a matter of a few days. Synoptic patterns with relatively weak tropospheric currents lead to the accumulation of PM10 ash at a re-gional scale all around Etna. In this context, closely interspersed paroxysms tend to accumulate very fine ash more diffusively in the lower troposphere and in stretched ash clouds higher up in the troposphere. Low-pressure, high-winds weather systems tend to stretch ash clouds into ~100 km-wide clouds forming large-scale vortices 800-1600 km in diameter. Daily average PM10 ash concentrations commonly exceed the aviation hazard threshold up to 1000 km downwind from the volcano and up to the upper troposphere for intense paroxysms. Vertical distributions show ash cloud thicknesses in the range 0.7–3 km, and PM10 sometimes stagnating at ground level, represent a potential health hazard.

Enterovirus 71 (EV71) infection hand-foot-mouth disease (HFMD), meningoencephalitis, neonatal sepsis, and even fatal encephalitis in children, thereby representing a serious public health hazard. It is important to determine the mechanisms underlying the regulation of EV71 infection. In this study, we initially reveal that the interleukin enhancer binding factor 2 (ILF2) down-regulates EV71 50% tissue culture infective dose (TCID50), attenuates EV71 plaque formation unit (PFU), thereby repressing EV71 infection. Moreover, we reveal a distinct mechanism by which EV71 antagonizes ILF2-mediated antiviral effects. Chip data analyses show that ILF2 mRNA is reduced upon EV71 infection. Cellular studies indicate that EV71 infection represses ILF2 mRNA expression and protein production in human leukemic monocytes (THP-1) differentiated macrophages and in human rhabdomyosarcoma (RD) cells. Additionally, EV71 non-structural protein 2B interacts with ILF2 in human embryonic kidney (HEK293T) cells. Interestingly, in the presence of EV71 2B, ILF2 is translocated from the nucleus to the cytoplasm and co-localizes with 2B in the cytoplasm. Therefore, we reveal a distinct mechanism by which EV71 antagonizes ILF2-mediated antiviral effects by inhibiting ILF2 expression and promoting ILF2 translocation from the nucleus to cytoplasm through its 2B protein.

The pathogenesis of coronavirus disease 2019 (COVID-19) is associated with a hyperinflammatory response. The mechanisms of SARS-CoV-2-induced inflammation are scantly known. Methylglyoxal (MG) is a glycolysis-derived by-product, endowed with a potent glycating action, leading to the formation of advanced glycation end products (AGEs), the major of which is MG-H1. MG-H1 exerts strong pro-inflammatory effects, frequently mediated by the receptor for AGEs (RAGE). Here, we investigated the involvement of MG-H1/RAGE axis as a potential novel mechanism in SARS-CoV-2-induced inflammation by resorting to human bronchial (BEAS-2B) and alveolar (A549) epithelial cells, expressing different levels of ACE2 receptor (R), exposed to SARS-CoV-2 spike protein 1 (S1). Interestingly, we found in BEAS-2B cells that do not express ACE2-R, that S1 exerted a pro-inflammatory action through a novel MG-H1/RAGE-based pathway. RAGE expression levels in nasopharyngeal swabs from SARS-Cov-2 positive and negative individuals, as well as glyoxalase 1 expression, the major scavenging enzyme of MG, seem to support the results obtained in vitro. Altogether, our findings reveal a novel mechanism involved in the inflammation triggered by S1, paving the way to the study of MG-H1/RAGE inflammatory axis in SARS-CoV-2 infection as a potential therapeutic target to mitigate COVID-19 associated pathogenic inflammation.